Life Sciences case study: eXmoor

Pioneering advanced cell and gene therapy manufacturing with global impact

eXmoor was founded in 2004 as a biopharmaceutical and cell therapy manufacturing consultancy. Over the years, the company has evolved into a globally recognised leader in the field, having completed over 550 projects across 16 countries. Initially focused on traditional biopharmaceuticals, eXmoor shifted its focus to cell and gene therapies as these emerging technologies began to take shape in the mid-2000s. This strategic pivot has positioned eXmoor at the cutting edge of advanced therapeutic manufacturing.

Key achievements

Global reach

eXmoor has successfully completed more than 550 projects across 16 countries, establishing itself as a prominent player in the biopharmaceutical and cell therapy sectors.

Strategic shift

The company adapted to the growing field of cell and gene therapy in 2007, bringing in new expertise and skillsets to meet the demands of this evolving market.

Growth at FutureSpace

In 2017, eXmoor moved into FutureSpace, a tech accelerator based at the University of the West of England, which facilitated its continued growth and development.

Major investment

In May 2023, eXmoor secured $35 million in Series A funding, enabling the launch of the eXmoor Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility.

Regulatory milestone

In 2024, the Cell and Gene Therapy Centre received its Manufacturing and Import Authorisation for Investigational Medicinal Products (MIA(IMP)) license from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This license signifies the successful culmination of a two-year project to design and build a state-of-the-art advanced therapies manufacturing facility.

Image credit: eXmoor Pharma

Future plans

eXmoor aims to build on its recent successes by focusing on the following areas:

Expansion of manufacturing capabilities: Leveraging the new Cell and Gene Therapy Centre to enhance its manufacturing capabilities for autologous and allogeneic cell therapies and viral vectors.
Innovation and development: Continuing to advance its technology and expertise in cell and gene therapies, further establishing itself as a leading global contract development and manufacturing organisation (CDMO).
Global growth: Expanding its global footprint to support the increasing demand for advanced therapies and solidify its position as a key player in the industry.